−Removed: Our corporate headquarters are located in Marina del Rey, California, with an address of 4503 Glencoe Avenue, Marina del Rey, CA 90292, where we currently lease 35,500 square feet of laboratory and office space.
+Added: Our corporate headquarters are located in Los Angeles, California, with an address of 5005 McConnell Avenue, Los Angeles, CA 90066.
+Added: On October 28, 2021, we entered into a lease for approximately 56,300 sq.
+Added: of office, research and development and manufacturing space under a non-cancellable lease (the “2021 Lease”).
+Added: The 2021 Lease payment start date was May 1, 2022, and the total lease term is for 16 years and runs through 2038.
+Added: Office space and research laboratories have been fully occupied since the third quarter of 2023, with cGMP manufacturing space (~10,000 sq.
+Added: ft.) expected to be fully constructed and occupied in the second half of 2024.
+Added: We have a property located in Marina del Rey, California, with an address of 4503 Glencoe Avenue, Marina del Rey, CA 90292, where we currently lease 35,500 square feet of laboratory and office space.
The lease expires on December 31, 2031.
The facility includes 19,500 square feet of BSL2 laboratory space dedicated to phage product development.
−Removed: The facility includes approximately 3,000 square feet of cGMP laboratory space, designed to produce clinical quantities of our phage product candidates for human trials and to perform in-house Quality Control (“QC”) testing.
−Removed: On October 28, 2021, we entered into a lease for office and research and development space under a non-cancellable lease in Los Angeles, CA (the “2021 Lease”).
−Removed: The 2021 Lease payment start date was May 1, 2022, and the total lease term is for 16 years and runs through 2038.
−Removed: Monthly rent for 2022 and 2023 will be fully or partially abated while we and the lessor complete planned tenant improvements to the facility, expected to be completed in the second half of 2023.
−Removed: Base monthly rent will be approximately $0.25 million in 2024.
−Removed: We are entitled to receive an allowance for tenant improvements of up to $7.3 million.
+Added: The facility includes approximately 3,000 square feet of cGMP laboratory space, designed to produce clinical quantities of our phage product candidates for human trials and to perform in-house QC testing.
+Added: We are actively seeking a sub-tenant to take over the remaining term of the lease from mid-2024.
In addition, we lease a 5,000 square foot facility located in Sydney, Australia, which includes 4,000 square feet of laboratory space providing capabilities to support phage product development and manufacturing process development.
−Removed: The facility is also set up to provide microbiological support of clinical trials.
−Removed: We occupy approximately 1,000 square feet of leased office space pursuant to a month-to-month sublease, located at 3579 Valley Centre Drive, Suite 100, San Diego, California 92130.
−Removed: We believe that our existing office and laboratory space is sufficient to meet our needs for the foreseeable future and that suitable additional space will be available when and if needed.
+Added: We believe that our existing office and laboratory space is sufficient to meet our needs for the foreseeable future.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.